Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 186 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic Pontine Glioma Linked to TP53 Alterations A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab MOST POPULAR Abnormal Results from Prenatal Blood Test Could Point to Cancer in... February 21, 2025 Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients... February 24, 2026 New Survey Highlights the Role of Clinical Practice Guidelines to Improve... March 12, 2026 Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant... June 18, 2021 Load more HOT NEWS Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy... Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 Life beyond cancer: Improving the long term side effects for children... Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:...
